Table 1.
Incident dementia and mild cognitive impairment in the Women's Health Initiative Memory Study and the Multiple Outcomes of Raloxifene Evaluation trial
| Trial / clinical outcome | Number contributing to analysis | Active intervention | Mean follow-up | Number of events in active group | Number of events in placebo group | Hazard ratio (95% confidence interval) |
|---|---|---|---|---|---|---|
| WHIMS / all-cause dementia | ||||||
| Uterus26 | 4532 | CE+MPA | 4.1 y | 40 | 21 | 2.1 (1.2 to 3.5) |
| No uterus27 | 2947 | CE | 5.2 y | 28 | 19 | 1.5 (0.8 to 2.7) |
| Both combined27 | 7471 | – | – | 68 | 40 | 1.8 (1.2 to 2.6) |
| WHIMS / mild cognitive impairment | ||||||
| Uterus26 | 4532 | CE+MPA | 4.0 y | 56 | 55 | 1.1 (0.7 to 1.6) |
| No uterus27 | 2947 | CE | 5.1 y | 76 | 58 | 1.3 (0.95 to 1.9) |
| Both combined27 | 7471 | – | – | 132 | 103 | 1.3 (0.97 to 1.6) |
| MORE / all-cause dementia 42 | 3525 | Raloxifenea | 3.0 y | 17 | 18 | 0.9 (0.5 to 1.8) |
| MORE / Alzheimer's disease 42 | 8 | 15 | 0.5 (0.2 to 1.2) | |||
| MORE /mild cognitive impairment 42 | 44 | 63 | 0.7 (0.5 to 0.98) | |||
CE = conjugated estrogens, 0.625 mg/d; MORE = Multiple Outcomes of Raloxifene Evaluation; MPA = medroxyprogesterone acetate, 2.5 mg/d; WHIMS = Women's Health Initiative Memory Study.
a
Raloxifene 120 mg/d; for standard dose raloxifene (60 mg/d), cognitive outcomes did not differ significantly from placebo (results not shown).